Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO. This is an ASCO ...
Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort. This is an ASCO Meeting ...
Interpretable Artificial Intelligence (AI) and Edge computing have the potential to revolutionize the diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results